Nicola J Smith,Ian Reddin,Paige Policelli,Sunwoo Oh,Nur Zainal,Emma Howes,Benjamin Jenkins,Ian Tracy,Mark Edmond,Benjamin Sharpe,Damian Amendra,Ke Zheng,Nagayasu Egawa,John Doorbar,Anjali Rao,Sangeetha Mahadevan,Michael A Carpenter,Reuben S Harris,Simak Ali,Christopher Hanley,Rémi Buisson,Emma King,Gareth J Thomas,Tim R Fenton

Abstract:Two APOBEC DNA cytosine deaminase enzymes, APOBEC3A and APOBEC3B, generate somatic mutations in cancer, thereby driving tumour development and drug resistance. Here, we used single-cell RNA sequencing to study APOBEC3A and APOBEC3B expression in healthy and malignant mucosal epithelia, validating key observations with immunohistochemistry, spatial transcriptomics and functional experiments. Whereas APOBEC3B is expressed in keratinocytes entering mitosis, we show that APOBEC3A expression is confined largely to terminally differentiating cells and requires grainyhead-like transcription factor 3 (GRHL3). Thus, in normal tissue, neither deaminase appears to be expressed at high levels during DNA replication, the cell-cycle stage associated with APOBEC-mediated mutagenesis. In contrast, in squamous cell carcinoma we find that, there is expansion of GRHL3expression and activity to a subset of cells undergoing DNA replication and concomitant extension of APOBEC3A expression to proliferating cells. These findings suggest that APOBEC3A may play a functional role during keratinocyte differentiation, and offer a mechanism for acquisition of APOBEC3A mutagenic activity in tumours.

Differentiation signals induce APOBEC3A expression via GRHL3 in squamous epithelia and squamous cell carcinoma